Miguel A Luque-Fernandez
Overview
Explore the profile of Miguel A Luque-Fernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bogdanet D, Castillo M, Doheny H, Dervan L, Luque-Fernandez M, Halperin J, et al.
Diabet Med
. 2023 Apr;
40(9):e15121.
PMID: 37078256
Aims: Gestational diabetes (GDM) is associated with the development of postpartum (PP) glucose intolerance. Plasma glycated CD59 (pGCD59) is an emerging biomarker for the detection of hyperglycaemia. The aim of...
2.
Smith M, Mansournia M, Maringe C, Zivich P, Cole S, Leyrat C, et al.
Stat Med
. 2021 Oct;
41(2):407-432.
PMID: 34713468
The main purpose of many medical studies is to estimate the effects of a treatment or exposure on an outcome. However, it is not always possible to randomize the study...
3.
Luque-Fernandez M, Goncalves K, Salamanca-Fernandez E, Redondo-Sanchez D, Lee S, Rodriguez-Barranco M, et al.
Eur J Cancer
. 2020 Mar;
129:4-14.
PMID: 32114366
Background: Numerous studies have analysed the effect of comorbidity on cancer outcomes, but evidence on the association between multimorbidity and short-term mortality among colorectal cancer patients is limited. We aimed...
4.
Ghosh P, Luque-Fernandez M, Vaidya A, Ma D, Sahoo R, Chorev M, et al.
Diabetes Care
. 2017 Apr;
40(7):981-984.
PMID: 28450368
Objective: Plasma glycated CD59 (pGCD59) is an emerging biomarker in diabetes. We assessed whether pGCD59 could predict the following: the results of the glucose challenge test (GCT) for screening of...